Burning Rock Biotech Ltd
NASDAQ:BNR
Intrinsic Value
Burning Rock Biotech Ltd. engages in the investment of medical fields. [ Read More ]
The intrinsic value of one
BNR
stock under the Base Case scenario is
2.19
USD.
Compared to the current market price of 0.86 USD,
Burning Rock Biotech Ltd
is
Undervalued by 61%.
Burning Rock Biotech Ltd's market capitalization is 88.3m USD.
BNR stock price is 0.86 USD.
BNR stock price (0.86 USD) is 61% less than its Intrinsic Value (2.19 USD).
BNR.
BNR's Revenue has dropped by 5% over the past 12 months.
BNR's Revenue has been growing by 8% per year for the last 3 years.
BNR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -119% to -129%, and is approaching profitability.
BNR's Revenue is forecast to grow at a rate of 29% per year over the next 3 years.
BNR's ROE (Return on Equity) has significantly decreased in the last 3 years from -35% to -68%, and is approaching profitability.
BNR has negative Operating Income for the last twelve months.
BNR has negative Net Income for the last twelve months.
BNR's ROE (Return on Equity) for the past 12 months is negative and is equal to -68%.
BNR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -129%.
BNR has positive Gross Profit for the last twelve months.
BNR has negative Free Cash Flow for the last twelve months.
BNR's short-term assets (884m CNY) exceed its short-term liabilties (263m CNY).
BNR's long-term assets (1B CNY) exceed its long-term liabilties (272m CNY).
BNR has negative three-year average ROE (Return on Equity): -50%. The company is not efficient at transforming stockholders' equity into net income.
BNR has negative three-year average ROIC (Return on Invested Capital): -135%. The company is not efficient at using invested capital to generate operating income.
BNR's D/E (Debt to Equity) is very low and is equal to 0.
BNR's Altman Z-Score is very low and is equal to -6.58.
Valuation Backtest
Burning Rock Biotech Ltd
Run backtest to discover the historical profit from buying and selling
BNR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Burning Rock Biotech Ltd
Balance Sheet Decomposition
Burning Rock Biotech Ltd
| Current Assets | 884.1m |
| Cash & Short-Term Investments | 615.1m |
| Receivables | 149.6m |
| Other Current Assets | 119.4m |
| Non-Current Assets | 155.9m |
| Long-Term Investments | 337k |
| PP&E | 144.2m |
| Intangibles | 964k |
| Other Non-Current Assets | 10.4m |
| Current Liabilities | 263.4m |
| Accounts Payable | 18.1m |
| Accrued Liabilities | 113.6m |
| Other Current Liabilities | 131.7m |
| Non-Current Liabilities | 8.2m |
| Other Non-Current Liabilities | 8.2m |
Earnings Waterfall
Burning Rock Biotech Ltd
|
Revenue
|
537.4m
CNY
|
|
Cost of Revenue
|
-174.2m
CNY
|
|
Gross Profit
|
363.2m
CNY
|
|
Operating Expenses
|
-1B
CNY
|
|
Operating Income
|
-669.3m
CNY
|
|
Other Expenses
|
15.6m
CNY
|
|
Net Income
|
-653.7m
CNY
|
Free Cash Flow Analysis
Burning Rock Biotech Ltd
What is Free Cash Flow?
BNR Profitability Score
Profitability Due Diligence
Burning Rock Biotech Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Burning Rock Biotech Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BNR Solvency Score
Solvency Due Diligence
Burning Rock Biotech Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Burning Rock Biotech Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNR Price Targets Summary
Burning Rock Biotech Ltd
Shareholder Return
BNR Price
Burning Rock Biotech Ltd
| Average Annual Return | -45.93% |
| Standard Deviation of Annual Returns | 40.49% |
| Max Drawdown | -98% |
| Market Capitalization | 88.3m USD |
| Shares Outstanding | 102 675 000 |
| Percentage of Shares Shorted | 0.46% |
Company Profile
Burning Rock Biotech Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
BNR
stock under the Base Case scenario is
2.19
USD.
Compared to the current market price of 0.86 USD,
Burning Rock Biotech Ltd
is
Undervalued by 61%.
You don't have any saved screeners yet
